New hope for children in shock: experimental drug targets low blood pressure
NCT ID NCT07212686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Angiotensin II in children under 18 with life-threatening low blood pressure (vasodilatory shock) that hasn't improved with fluids or standard medicines. The goal is to see if the drug can safely raise blood pressure and reduce the need for other strong blood pressure medications. Researchers will monitor vital signs, blood work, and kidney blood flow, with a follow-up call at 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASODILATORY SHOCK are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cohen Children's Medical Center
Queens, New York, 11101, United States
-
Cohen Children's Medical Center of Northwell Health
New Hyde Park, New York, 11040, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.